Wei, Jonathan C. J. http://orcid.org/0000-0003-0222-5425
Haridass, Isha N.
Crichton, Michael L.
Mohammed, Yousuf H.
Meliga, Stefano C.
Sanchez, Washington Y.
Grice, Jeffrey E.
Benson, Heather A. E.
Roberts, Michael S.
Kendall, Mark A. F.
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1107356)
Article History
Received: 9 July 2018
Accepted: 9 November 2018
First Online: 10 December 2018
Competing Interests
: J.C.J.W. and M.L.C. were former Vaxxas (a company developing the Nanopatch for clinical trials) staff employed through UQ until prior to commencing on this work. M.A.F.K. was a former board member of Vaxxas. The Nanopatch technology has been licensed by UQ to Vaxxas for use in clinical development. There has been no financial support for this work that could have influenced its outcome.